Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya26944Research ArticleHigh efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)SeryakovA Palseryakov@yandex.ruOvchinnikovaL K-ZabelinM V-YakubovT Z-SidorovD B-OvchinnikovM V-15062014162333709042020Copyright © 2014, Consilium Medicum2014A case report of lapatinib + capecitabin effective treatment in patient with bilateral HER2+ER+ breast cancer progressing on trastuzumab-containing therapy with brain metastases.HER2breast cancerHER2progression on trastuzumabbrain metastaseslapatinibрак молочной железыпрогрессирование на трастузумабеметастазы в головной мозглапатиниб[Dawood S, Broglio K, Buzdar A.U et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional - based review. J Clin Oncol 2010; 28 (1): 92-8.][Geyer C, John Forster M.D, Deborah M.S et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Engl J Med 2006; 355 (26): 2733-43.][Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine vs capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112 (3): 533-43.][Фролова М.А., Тюляндин С.А. Лапатиниб в лечении рака молочной железы: история клинического развития препарата и собственный опыт применения. Рус. мед. журн. 2008; 16 (13):921-7.]